Dr. Yawei Jenny Yang

Individuals who were already pregnant at the beginning of the COVID-19 pandemic had a 50 percent lower exposure to...

The long-term immune response to SARS-CoV-2 mRNA vaccination was similar in pregnant individuals compared with non-pregnant individuals of reproductive age.

Vaccination against COVID-19 had no impact on the health of placentas in pregnant women.

COVID-19 vaccination of expectant mothers elicits levels of antibodies to the SARS-CoV-2 outer “spike” protein at the time of delivery that don’t vary dramatically with the timing of vaccination during pregnancy and thus don’t justify delaying vaccination, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Women who receive COVID-19 mRNA vaccines produced by Pfizer-BioNTech or Moderna while in their third trimester of pregnancy generate a strong immune response and pass protective antibodies through umbilical cord blood to their babies.

Antibodies that guard against COVID-19 can transfer from mothers to babies while in the womb, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researcher.

Weill Cornell Medicine has awarded eight grants of $100,000 each to faculty for a variety of research projects on COVID-19, funded by the institution’s Board of Overseers and additional donors. The grants will support studies aimed at understanding fundamental aspects of the disease, the body’s immune response and social determinants of health that affect COVID-19 outcomes.